This site is for healthcare professionals only. If you are not a healthcare professional please click here

Prescribing information and adverse event reporting information can be found at the bottom of this webpage.

Genitourinary (GU) Masterclass 2025

Amsterdam, Netherlands

4–5 July 2025

Meeting Co-Chairs:

Professor Thomas Powles,

United Kingdom

Dr Michiel van der Heijden,

Netherlands

Professor Bertrand Tombal,

Belgium

Professor André Bergman,

Netherlands

Thank you for your active participation during the recent Astellas-sponsored GU Masterclass. Here you will find short videos that showcase the daily highlights from our Co-Chairs, as well as the slide content from all sessions.

UK Prescribing Information is available for PADCEV™▼ (enfortumab vedotin) here. Dutch Prescribing Information for PADCEV™▼(enfortumab vedotin) is available here.

UK Prescribing Information is available for XTANDI™(enzalutamide) here. Dutch Prescribing Information for XTANDI™(enzalutamide) is available here.

PADCEV indications:

EV, in combination with P, is indicated for the 1L treatment of adult patients with unresectable/mUC who are eligible for platinum-containing chemotherapy
EV as monotherapy is indicated for the treatment of adult patients with LA/mUC who have previously received a platinum-containing chemotherapy and a PD-1/L1 inhibitor

▼This medicinal product is subject to additional monitoring.

XTANDI is indicated:

As monotherapy or in combination with androgen deprivation therapy for the treatment of adult men with high-risk biochemical recurrent nmHSPC who are unsuitable for salvage-radiotherapy
In combination with androgen deprivation therapy for the treatment of adult men with mHSPC
For the treatment of adult men with high-risk non-metastatic CRPC
For the treatment of adult men with metastatic CRPC who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated
For the treatment of adult men with metastatic CRPC whose disease has progressed on or after docetaxel therapy

NL: Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. Nederland: Nederlands Bijwerkingen Centrum Lareb;
Website: www.lareb.nl

UK: Adverse events should be reported.

Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for ‘MHRA yellow card’ in the Google Play Store or Apple App Store. Adverse events should also be reported to Astellas Pharma Ltd on 0800 783 5018

1L, first line; CRPC, castration-resistant prostate cancer; EV, enfortumab vedotin; mUC, metastatic urothelial carcinoma; mHSPC, metastatic hormone-sensitive prostate cancer; nmHSPC, non-metastatic hormone-sensitive prostate cancer; P, pembrolizumab; PD-1/L1, programmed cell death protein/death-ligand 1; UC, urothelial carcinoma.